Saudi Arabia-based Tabuk Pharmaceuticals, which has a strong presence across the MENA region, including KSA, Gulf Countries, North Africa and LEVANT, offers a wide range of services by developing, manufacturing, marketing, and distributing branded and generic pharmaceutical products.
Being the leading company in the Saudi private market and the second leading generic in MENA, Tabuk Pharmaceuticals is delivering on its commitment to promoting well-being and consistently enhancing healthcare outcomes.
Since its establishment in 1994, Riyadh-based Tabuk Pharmaceuticals has been consistently enhancing its research and development efforts to solidify its position as a trusted healthcare partner and positively influence health systems in the region.
Tabuk Pharmaceuticals, which has transformed itself from a family business to Saudi Arabia’s largest non-governmental pharmaceutical company, now has its in-house state-of-the-art R&D department with a team of experts who are developing best-in-class solutions to produce medicines for various therapeutic areas including cardiovascular, respiratory, central nervous, musculoskeletal, and gastrointestinal systems in addition to anti-infectives, pain management medications, and diabetes, with future expansion in key therapy areas as oncology, immunology and ophthalmology.
The company’s people-first philosophy and commitment to ethical, evidence-based practices have made it a reliable healthcare partner across the MENA region’s markets.
Tabuk Pharmaceuticals was recently awarded the “Best Contribution to the Pharmaceutical Sector – Saudi Arabia” by the Global Business Outlook (GBO), highlighting the organisation’s dedication to innovation, sustainable healthcare solutions, and expanding presence in the MENA region.
“We are a team of over 2,400 professionals across our four advanced manufacturing sites in Tabuk and Dammam in Saudi Arabia, Sudan, and Algeria. Our manufacturing sites produce over 2 billion base units annually to help maintain the health of millions of patients across 17 countries in the MENA region,” the business told the GBO.
As a leading private company in Saudi Arabia’s pharmaceutical sector, Tabuk has remained committed to actively supporting the Kingdom’s Vision 2030 objectives to boost the pharmaceutical sector’s manufacturing capabilities.
Moving forward, Tabuk Pharmaceuticals aims to strengthen its role as a reliable partner for the government health sector, private healthcare providers, and patients while continuing to deliver a transformative impact on therapeutic and health systems regionally.